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Abstract
Aims/hypothesis Additional safe and effective therapies for
type 2 diabetes are needed, especially ones that do not cause
weight gain and have a low risk of hypoglycaemia. The pres-
ent study evaluated albiglutide as monotherapy.
Methods In this placebo-controlled study, 309 patients (aged
≥18 years) with type 2 diabetes inadequately controlled by
diet and exercise and who were not using a glucose-
lowering agent (HbA1c 7.0–10.0% [53.00–85.79 mmol/mol],
body mass index 20–45 kg/m2, and fasting C-peptide
≥0.26 nmol/l) were randomised (1:1:1 on a fixed
randomisation schedule using an interactive voice response
system) to receive once-weekly albiglutide 30 mg (n=102)
or 50 mg (n=102) or matching placebo (n=105). The study
treatments were blinded to both patients and study personnel.
All study data were collected at individual patient clinic visits.
The primary efficacy endpoint was change in HbA1c from
baseline to week 52. The primary analysis was applied to the
intent-to-treat population. Additional efficacy and safety end-
points were assessed.
Results At week 52, both albiglutide 30 mg and 50 mg were
superior to placebo in reducing HbA1c. The least-squares
means treatment difference from placebo was −0.84% (95%
CI −1.11%, −0.58%; p<0.0001) with albiglutide 30 mg and
−1.04% (−1.31%, −0.77%; p<0.0001) with albiglutide
50 mg. Injection-site reactions were reported more frequently
with albiglutide (30 mg: 17.8%; 50 mg: 22.2%) than with
placebo (9.9%). Other commonly reported adverse events
included nausea, diarrhoea, vomiting and hypoglycaemia;
the incidences of these were generally similar across
treatment groups.
Conclusions/interpretation Albiglutide is safe and effective
as monotherapy and significantly lowered HbA1c levels over
52 weeks, did not cause weight gain, and had good gastroin-
testinal tolerability and a low rate of hypoglycaemia compared
with placebo.
Trial registration ClinicalTrials.gov NCT00849017
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The medical management of patients with type 2 diabetes
typically consists of diet and exercise, together with glucose-
lowering medications having different mechanisms of action
and possible side effects, including hypoglycaemia, weight
gain, gastrointestinal (GI) disturbances, genitourinary infec-
tions and fluid retention leading to oedema and/or heart fail-
ure, which may limit their use in some individuals [1, 2].
Approximately 50% of Americans with diabetes continue to
have HbA1c values above 7% (53.00 mmol/mol) [3] and,
while a systematic review showed there to be variability with
regard to attainment of an HbA1c goal of <7% (53.00 mmol/
mol) among the different classes of glucose-lowering agents,
glucagon-like peptide-1 (GLP-1) analogues achieved the
highest percentage [4]. There remains an ongoing need for
new treatments for type 2 diabetes that improve treatment
efficacy and reduce patient treatment burden.
The incretin hormone GLP-1 is secreted by intestinal L
cells following food ingestion. This hormone stimulates insu-
lin release in a glucose-dependent fashion, resulting in a low
risk of hypoglycaemia. In addition, native GLP-1 inhibits
prostprandial glucagon release, which in turn may lead to a
reduction in glucose release from the liver. Importantly, GLP-
1 has also been shown to delay gastric emptying and reduce
food intake, subsequently resulting in weight loss [5]. The
long-acting GLP-1 receptor (GLP-1R) agonist albiglutide is
made up of a GLP-1 dimer that is resistant to degradation by
dipeptidyl peptidase-4 (DPP-4) fused to recombinant human
albumin. Its extended duration of action (half-life of
approximately 5 days) allows for once-weekly dosing [6–8].
Other studies within the HARMONY phase 3 programme
have shown once-weekly albiglutide to be effective, generally
safe and well tolerated in combination with other oral glucose-
lowering medications [9–15].
In this 3 year phase 3 trial, we report the efficacy and safety
results at the 52 week primary endpoint of once-weekly
albiglutide (30 mg and 50mg) vs placebo in patients with type
2 diabetes inadequately controlled on a regimen of diet and
exercise.
Methods
Study design and participants HARMONY 2 was a 3 year,
randomised, placebo-controlled study evaluating the efficacy
and safety of subcutaneously injected albiglutide administered
as either 30 mg or 50 mg once a week. There were four study
periods: screening (2 weeks); run-in/stabilisation (4 weeks);
treatment (156 weeks, comprising 52 weeks for primary end-
point) and post-treatment follow-up (8 weeks).
Patients were recruited from 143 sites in the USA (133
sites; n=271) and Mexico (10 sites; n=38). Enrolled patients
were aged ≥18 years, with type 2 diabetes uncontrolled by diet
and exercise (HbA1c ≥7.0% [≥53.00 mmol/mol] and ≤10.0%
[≤85.79 mmol/mol]) and a BMI of 20–45 kg/m2. Key exclu-
sion criteria included history of type 1 diabetes and recent
cardiovascular and/or cerebrovascular disease (see full inclu-
sion and exclusion criteria and a list of investigators by coun-
try in the electronic supplementary material (ESM) Methods
and ESM Participating study investigators).
This study was conducted according to applicable regula-
tory and patient privacy requirements, good clinical practice
and the Declaration of Helsinki principles. The study protocol,
amendments and informed consent requiring pre-approval
were reviewed and approved by a national, regional or inde-
pendent ethics committee or institutional review board, in ac-
cordance with the International Conference on Harmonisation
of Technical Requirements for Registration of Pharmaceuti-
cals for Human Use Good Clinical Practice and applicable
country-specific requirements. All patients provided written
informed consent.
Randomisation and masking Random assignment of 105
patients to each of the three treatment groups in a 1:1:1 ratio
by an interactive voice response system was planned. Eligible
patients were stratified by screening HbA1c value (<8.0%
[<63.93 mmol/mol] vs ≥8.0% [≥63.93 mmol/mol]), history
of myocardial infarction (MI) (yes vs no) and age (<65 years
vs ≥65 years). Albiglutide and matching placebo were sup-
plied in as a fixed-dose (30 mg or 50 mg) pen injector system
designed to administer drugs via abdominal subcutaneous in-
jection. Both albiglutide and matching placebo contained the
same excipients added to either lyophilised albiglutide or
matching placebo. The study treatments were blinded to both
patients and study personnel.
Procedures Eligible patients were randomly assigned to re-
ceive either albiglutide 30 mg once weekly, albiglutide 30 mg
once weekly with uptitration to 50 mg at week 12, or placebo.
Standard dietary, exercise and home glucose monitoring ad-
vice for diabetic patients was provided prior to beginning
randomised treatment and this was reinforced at each study
centre visit through to the end-of-treatment visit. After week 2,
patients who experienced persistent hyperglycaemia qualified
for rescue (metformin and insulin preferred; ESM Table 1).
Major cardiovascular events (MI, stroke [including tran-
sient ischaemic attack and ischaemic neurological deficit])
and all deaths that occurred during treatment were adjudicated
by a Clinical Endpoint Committee and are part of an ongoing
meta-analysis. An independent, masked Pancreatitis Adjudi-
cation Committee adjudicated adverse events of suspected
pancreatitis. Safety was also monitored by an independent
data monitoring committee. The presence of albiglutide anti-
bodies was assessed with a validated ELISA and their
albiglutide-neutralising capacity was determined using a
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cell-based assay (see ESMMethods). Evaluation for systemic
allergic reactions (SARs) included investigator reporting and
standard Medical Dictionary for Regulatory Activities
(MedDRA) queries for anaphylaxis, angioedema and severe
cutaneous reaction (see ESM Methods).
Outcomes The primary efficacy endpoint was change in
HbA1c from baseline at week 52 for albiglutide vs placebo.
Secondary efficacy endpoints were change in fasting plasma
glucose (FPG) from basel ine over t ime, t ime to
hyperglycaemia rescue, the proportion of patients meeting
HbA1c treatment goals (<6.5% [<47.53 mmol/mol] and
<7.0% [<53.00 mmol/mol]) and body weight change from
baseline over time. Safety assessments included the occur-
rence of adverse events, serious adverse events and death.
Adverse events of special interest included GI events,
injection-site reactions (ISRs), cardiovascular events,
hypoglycaemia [16], pancreatitis, thyroid tumours, potential
SARs and immunogenicity. While the analysis of overall
hypoglycaemic events was pre-specified, analysis of events
that occurred pre-rescue was considered post hoc at the pri-
mary endpoint.
Statistical analysisUsing a two-sided, two-sample t test and a
sequential test-wise significance level of 0.05, with a mini-
mum of 89 patients in each albiglutide group, the albiglutide
vs placebo comparison had at least 91% power to reject the
null hypothesis of no treatment benefit if albiglutide treatment
superiority was ≥0.5% and the SD for HbA1c change from
baseline was ≤1.0%. To allow for a premature patient loss of
up to 15%, at least 105 patients were randomly assigned to
each treatment group.
The primary analysis of HbA1c change from baseline at
week 52 evaluated the intent-to-treat (ITT) population using
an ANCOVA model with treatment group, region, history of
MI and age (above/below 65 years) as factors and baseline
HbA1c as a continuous covariate. The ITT population includ-
ed all patients who received at least one dose of the study drug,
had a baseline HbA1c and had at least one post-baseline HbA1c
assessment. Imputation for missing observations was applied
to efficacy endpoints evaluated at or before week 52 using the
last observation carried forward (LOCF) method. Patients res-
cued from hyperglycaemia or discontinued from active treat-
ment before week 52 had their last HbA1c before the occur-
rence carried forward for the primary analysis. A sensitivity
analysis was performed using a multilevel regressionmodel of
repeated measures on change from baseline HbA1c through
week 52 [17].
HbA1c treatment effect was evaluated as the contrasts be-
tween the groups’ least-squares means relative to placebo. The
contrasts were evaluated inferentially using a two-sided t test
and a significance level of 0.05 in a sequentially ordered
analysis (albiglutide 50 mg vs placebo [superiority] then
albiglutide 30 mg vs placebo [superiority]) until the first test
in the order failed to reject the hypothesis.
The continuous secondary efficacy endpoints of change
from baseline over time in FPG and weight were analysed
analogous to the primary efficacy endpoint. The between-
group differences in time to hyperglycaemia rescue were com-
pared using pair-wise logrank tests within a Kaplan–Meier
model. The treatment comparison for the proportion of pa-
tients who achieved each of the clinically meaningful HbA1c
response levels was analysed using non-parametric, covari-
ance-adjusted, extended Mantel–Haenszel tests. As support-
ive analysis, logistic-regression models with effects for treat-
ment and other main effect variables (region, age category,
history of prior MI and baseline HbA1c category) were used
to quantify the observed treatment effects.
Safety analyses were applied to the safety population,
which included all randomly assigned patients who received
at least one dose of study treatment. Safety analyses included
comparative summaries of on-therapy adverse events and
rates up to 52 weeks (defined as events that occurred on-
therapy or within 56 days of last dose, regardless of rescue),
vital sign measurements, laboratory and physical examina-
tions and electrocardiogram assessments.
Statistical analyses were carried out with SAS version 9.1
(SAS Institute, Cary, NC, USA).
Role of funding source The study sponsor participated in
study design, data collection, review, analysis and report writ-
ing. All authors had full access to study data. The correspond-
ing author reviewed the trial report (signatory investigator),
had full access to study data and had final responsibility for
publication submission.
Results
Of the 479 patients assessed for eligibility in this study, 309
were randomly assigned to receive the following treatments:
albiglutide 30 mg (n=102); albiglutide 50 mg (n=102) or
placebo (n=105) (Fig. 1). The percentage of patients continu-
ing in the study through to week 52 included 85.3% on
albiglutide 30 mg, 72.5% on albiglutide 50 mg and 75.2%
on placebo (Fig. 1). Baseline demographics were similar be-
tween treatment groups (Table 1).
Over 52 weeks of treatment, HbA1c decreased from base-
line in both albiglutide groups and increased in the placebo
group (Fig. 2a). The treatment difference (albiglutide minus
placebo) of the model-adjusted least-squares mean change in
HbA1c from baseline to week 52 (ESM Table 2) was statisti-
cally significant for both albiglutide groups (albiglutide
30 mg: −0.84% [95% CI −1.11%, −0.58%], p<0.0001;
albiglutide 50 mg: −1.04% [−1.31%, −0.77%], p<0.0001).
Post hoc sensitivity analyses of the primary efficacy endpoint
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were consistent with the primary efficacy results (ESM
Table 2). Changes in FPG at week 52 were consistent with
HbA1c results (Fig. 2b). The treatment difference was statisti-
cally significant for both albiglutide groups (albiglutide 30 mg
105 patients allocated to 
placebo group
309 patients randomised
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albiglutide 30 mg group
102 patients allocated to 
albiglutide 50 mg group
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Fig. 1 Patient disposition
throughout the study. The study
was ongoing at the time of data
analysis and the number of
patients who withdrew because of
an adverse event by week 52 was
reconciled to include two
additional patients in each of the
albiglutide treatment groups
Table 1 Baseline characteristics of study participants (safety population)
Characteristic Placebo (n=101) Albiglutide 30 mg weekly (n=101) Albiglutide 50 mg weekly (n=99)
Age (years) 53.1±11.7 53.6±10.9 52.0±11.8
Sex, male 58 (57.4) 58 (57.4) 50 (50.5)
Weight (kg) 95.4±19.9 95.8±19.6 97.10±17.8
BMI (kg/m2) 33.00±5.4 33.7±5.1 33.9±5.5
Baseline HbA1c (%) 8.0±0.9 8.0±0.8 8.2±0.9
Baseline HbA1c (mmol/mol) 64.2±9.9 64.5±9.5 66.2±10.3
Duration of diabetes (years) 4.3±4.0 3.4±3.7 4.2±4.6
Prior MI 4 (4.0) 3 (3.0) 2 (2.0)
Race
White 79 (78.2) 85 (84.2) 78 (78.8)
African-American/African 14 (13.9) 10 (9.9) 14 (14.1)
Asian 5 (5.0) 1 (1.0) 1 (1.0)
Ethnicity
Hispanic/Latino 29 (28.7) 30 (29.7) 26 (26.3)
Data are mean ± SD or n (%)
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vs placebo: −1.89 mmol/l [95% CI −2.55, −1.22], p<0.0001;
albiglutide 50 mg vs placebo: −2.38 mmol/l [−3.05, −1.71],
p<0.0001). At week 52, the HbA1c treatment goal of <7.0%
(53.00 mmol/mol) was met by 49.0%, 40.2% and 21.4% of
patients treated with albiglutide 30 mg, albiglutide 50 mg and
placebo, respectively (both p≤0.0002) and the goal of HbA1c
<6.5% (47.53 mmol/mol) was met by 25.0%, 24.7% and
10.2% of patients treated with albiglutide 30 mg, albiglutide
50 mg and placebo, respectively (both p<0.005).
The difference in the time to hyperglycaemia rescue was
statistically significant (Fig. 2c) in favour of each albiglutide
group (albiglutide 30 mg or 50 mg) (p<0.0001). At week 52,
more placebo patients (50.5%) used rescue therapy than pa-
tients in either albiglutide group (albiglutide 30 mg, 20.0%;
albiglutide 50 mg, 15.5%). Up to week 52, rescue probability
did not exceed 21.7% with albiglutide 30 mg and 18.6% with
albiglutide 50 mg, while the probability with placebo was as
high as 55.7%. Among patients requiring rescue medication,
metformin was the most commonly used; sulfonylureas
(glibenclamide, glimepiride or glipizide), insulin glargine
(A21Gly,B31Arg,B32Arg human insulin) and sitagliptin were
used by a small proportion of patients.
Weight loss was not statistically significantly different
when comparing the placebo and albiglutide groups at week
52 (least-squares mean change from baseline −0.39 kg with
albiglutide 30 mg, −0.86 kg with albiglutide 50 mg and
−0.66 kg with placebo).
For the safety profile at week 52, the proportion of patients
experiencing adverse events was higher with albiglutide 30 mg
and albiglutide 50 mg than with placebo (Table 2). More
albiglutide-treated patients withdrew from the study because
of adverse events, the main reasons in the 50 mg group being
GI events (n=3) and ISRs (n=4). However, 5 of the 13 patients
in the albiglutide 50 mg group were on the 30 mg dose at the
time of withdrawal. The incidence of serious adverse events
(fatal and non-fatal) at week 52 was similar across the two
albiglutide treatment groups and higher than in the placebo
group; there were no on-therapy serious adverse events report-
ed by more than one patient in any treatment group. A total of
three deaths was reported up to week 52 (all in the albiglutide
50 mg group)—one due to drowning and two due to cancer
(B-cell lymphoma and lung adenocarcinoma)—none of which
were considered by the investigator to be related to the study
drug. There were no reports of acute pancreatitis or thyroid
cancer during this study. Only small changes in the incidence
of adverse events, including serious adverse events, were ob-
servedwhen comparing on-therapy adverse events overall with
on-therapy adverse events prior to rescue from hyperglycaemia
with other glucose-lowering medications (mostly metformin)
that were added to albiglutide (ESM Table 3).
The most common adverse events reported with albiglutide
were GI events and ISRs. The frequency of all GI events was
similar across groups: 31.7% and 30.3% with albiglutide
30 mg and 50 mg, respectively, and 26.7% with placebo. The
reported incidence of nausea, diarrhoea, and constipation
events was similar among the treatment groups (Table 2), and
the incidence of vomiting was low in all groups but higher with
albiglutide 30 mg and 50 mg (3.0% in each) than with placebo
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Fig. 2 (a, b) Mean change in HbA1c (a) and FPG (b) from baseline
through to week 52. Data are means ± SEM. Blue diamonds, placebo
(n=99); green squares, albiglutide 30 mg (n=100); red triangles,
albiglutide 50 mg (n=97) uptitration at week 12. To convert values for
HbA1c in DCCT% into mmol/mol, subtract 2.15 and multiply by 10.929.
(c) Kaplan–Meier plot of probability of hyperglycaemic rescue. Blue line,
placebo; green line, albiglutide 30 mg; red line, albiglutide 50 mg. HbA1c
and FPG analyses were for the ITT population with LOCF; Kaplan–
Meier plot of probability of hyperglycaemic rescue was for the ITT
population
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a peak (4–5%) within the first weeks after initiation of
albiglutide and thereafter fluctuated between 1% and 3% at
any given time point up to week 52 (Fig. 3a). A similar pattern
was observed for diarrhoea, which rose to a peak (3–5%)
within the first weeks after initiation of albiglutide and
thereafter fluctuated between 0% and 4% over 52 weeks
(Fig. 3b). No dose–response relationship was observed for
the 30 mg and 50 mg curves for any of these GI events.
ISRs (most commonly reported as a reaction, erythaema,
rash or haematoma at the injection site) were reported more
frequently with both albiglutide dose groups than with place-
bo (Table 2), but a dose–response relationship was not
observed. Among patients with ISRs in the albiglutide groups,
50–69% of patients experienced one or two events, most had
mild events and the withdrawal rate was low (4%), although
higher than placebo (0%).
Documented symptomatic hypoglycaemia (≤3.9 mmol/l
[70 mg/dl]) occurred in one patient treated with albiglutide
30mg; therewere no reports of severe hypoglycaemia (Table 2
and ESM Table 4).
The incidence and total number of investigator-assessed
cardiovascular adverse events were lower in the albiglutide
50 mg group (8.1%, 12 events) than in the albiglutide 30 mg
(16.8%, 28 events) and placebo groups (16.8%, 23 events).
Table 2 On-therapy adverse events at week 52 (safety population)





Any adverse event 77/76.2/329 79/78.2/411 81/81.8/349
Serious adverse event 8/7.9/7.9 11/10.9/13.2 10/10.1/11.4
Related adverse event 21/20.8/60.3 35/34.7/120 36/36.4/94.1
Adverse event leading to withdrawal 2/2.0/2.0 5/5.0/4.7 13/13.1/13.4
Most common adverse event (≥6.0% in either albiglutide group), by preferred term (n/%/ratea)
Injection-site reaction 2/2.0/29.6 9/8.9/35.6 14/14.1/34.0
Diarrhoea 12/11.9/14.8 10/9.9 /15.0 13/13.1/15.5
Nausea 8/7.9/7.9 10/9.9/11.3 9/9.1/10.3
Upper respiratory tract infection 10/9.9/10.9 6/5.9/5.6 9/9.1/11.4
Nasopharyngitis 6/5.9/5.9 6/5.9/7.5 7/7.1/7.2
Sinusitis 2/2.0/2.0 3/3.0/2.8 7/7.1/10.3
Urinary-tract infection 3/3.0/5.9 1/1.0/0.9 6/6.1/8.3
Headache 14/13.9/18.7 10/9.9/15.0 6/6.1/8.3
GI adverse event (n/%/ratea)
Any event 27/26.7/41.4 32/31.7/49.7 30/30.3/51.6
Gastro-oesophageal reflux disease 2/2.0/2.0 1/1.0/0.9 4/4.0/4.1
Constipation 3/3.0/3.0 2/2.0/1.9 3/3.0/3.1
Vomiting 1/1.0/1.0 3/3.0/2.8 3/3.0/4.1
Dyspepsia 3/3.0/3.0 2/2.0/2.8 1/1.0/1.0
Pre-rescue hypoglycaemic event (n/%/rateb)
Any hypoglycaemic event 4/4.0/5.65 6/5.9/9.46 6/6.1/10.09
Severe 0/0/0 0/0/0 0/0/0
Documented symptomatic 2/2.0/2.83 1/1.0/2.10 0/0/0
ISR, n (%)
Any ISR 10 (9.9) 18 (17.8) 22 (22.2)
Mild ISR eventc 44 (100) 82 (90) 49 (89)
Withdrawal due to an ISR 0 (0) 4 (4.0) 4 (4.0)
No. of patients with one or two ISR events among patients with an ISR 8/10 (80) 9/18 (50) 15/22 (68)
a Event rate per 100 patient-years
b Event rate per patient-year. American Diabetes Association criteria [16]: Severe—event requiring another person to administer a resuscitative action;
Documented symptomatic—plasma glucose concentration ≤3.9 mmol/l (70 mg/dl) and presence of hypoglycaemic symptoms.While analysis of overall
hypoglycaemic events was pre-specified, analysis of events that occurred pre-rescue was considered post hoc at the primary endpoint; the number of
patients with one or two ISR events was also considered post hoc
c The bracketed numbers are percentages of mild ISR events with total ISR events as the denominator
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Small trends for lower blood pressure were observed, and
heart rate changes from baseline in the albiglutide treatment
groups compared with placebo showed increases of
1–2 beats per min (ESM Table 5).
There were no reports of serious events of angioedema or
anaphylaxis during this study (see Systemic allergic reactions
in the ESM Methods). The proportion of patients who devel-
oped anti-albiglutide antibodies was low (5.5% at any visit)
and none of the antibodies detected were neutralising. Assess-
ment of data for haematology, serum chemistry, lipid profile,
vital signs, electrocardiogram readings and physical examina-
tions generally produced unremarkable findings.
Discussion
It is important to conduct studies of monotherapy in patients
with type 2 diabetes because they provide evidence of a drug’s
safety and efficacy without the influence of other glucose-
lowering drugs. Our findings showed that albiglutide 30 mg
and 50 mg administered once weekly provided a rapid, clini-
cally relevant and durable glycaemic lowering through to the
primary endpoint at week 52. Results for the secondary end-
points (FPG, HbA1c targets and time to hyperglycaemic res-
cue) were supportive of the primary endpoint. Modest weight
loss was observed in all groups, including placebo, and a low
hypoglycaemic potential was demonstrated.
The placebo-subtracted reduction in HbA1c observed with
the albiglutide 50 mg dose in this study was comparable with
results from liraglutide and dulaglutide placebo-controlled
monotherapy studies and was greater than the reduction ob-
served with exenatide and lixisenatide [18–21]. Albiglutide
treatment produced a rapid effect on FPG; there was a steep
decline from baseline up to week 2 and the reduced levels were
maintained through toweek 52. These data are further supported
by albiglutide’s sustained effect, as demonstrated by the lower
proportion of patients who required rescue from hyperglycaemia
in the albiglutide vs placebo groups and by the proportion of
patients treated with both doses of albiglutide who achieved a
treatment goal of HbA1c <7% (<53.00 mmol/mol). A greater
proportion of patients receiving 30 mg albiglutide achieved an
HbA1c <7%, which may have been due to the higher starting
HbA1c value in patients in the group receiving the 50 mg dose.
Molecular size and other properties may have an impact on
the effect relative to other compounds in the central nervous
system. As a large albumin-based molecule, albiglutide (ap-
proximately 72 kDa) may not readily cross the blood–brain
barrier or diffuse into the brain at the area postrema (vomiting
centre) or hypothalamus (centre for the regulation of appetite
and food intake) where there is a breakdown in the blood–
brain barrier and thus it may have a more restricted access to
the central nervous system than the smaller GLP-1 peptides.
This may explain the finding that weight loss with albiglutide
did not differ significantly from that with placebo and is an
area where further research is needed.
With few exceptions, the safety profile was comparable
across the three treatment groups over 52 weeks. Consistent
with the known profile of GLP-1 agonists [22], GI events
were among the most common adverse events in the
albiglutide groups. However, diarrhoea and nausea were also
among the most common in the placebo group. Additionally,
the frequency of nausea and vomiting reported with
albiglutide in this study are consistent with those reported in
other albiglutide studies [6–8] and were generally lower than
has been reported in studies with liraglutide and exenatide
[23]. Moreover, in clinical trials of albiglutide that included
exenatide [8] and liraglutide [9] comparator arms the inci-
dence of GI adverse events was lower with albiglutide com-
pared with the other GLP-1R agonists. These differences in GI
tolerability profiles may be due in part to differences in the
time taken to reach maximum blood concentration (3–4 days
for albiglutide; a matter of hours for both exenatide and
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Fig. 3 Nausea/vomiting (a) and diarrhoea events (b) over time to week
52. Analyses are for the safety population, defined as all randomised
patients who received at least one dose of study drug. Blue lines, placebo
(n=101); green lines, albiglutide 30 mg (n=101); red lines, albiglutide
50 mg (n=99) uptitration at week 12
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albiglutide and its likely inability to cross the blood–brain
barrier may also account for the difference in GI tolerability
when comparing albiglutide with other members of its class.
Both efficacy measurements and adverse events have been
partly linked to centrally mediated effects [26, 27].
In this current study, although ISRs occurred with both
placebo and albiglutide, the incidence was higher with
albiglutide. However, events were generally mild and mostly
did not lead to withdrawal from the study. Since incretin-based
therapies have a glucose-dependent mechanism of action,
albiglutide was expected to have a low hypoglycaemic poten-
tial and this was further supported by data from this study.
When considering differences between the 30mg and 50mg
doses of albiglutide, a dose–response relationship was observed
for glycaemic variables but the adverse event profiles were
comparable with no dose-related trends. A partial explanation
for the latter finding could be tolerance or tachyphylaxis to
some reported adverse events. Although it is clinically impor-
tant to assess differences between the 30 mg and 50 mg doses
of albiglutide, this study was not powered to do so.
A limitation of this study was the omission of a clinically
relevant comparator. However, the comparison against place-
bo provided the best data with which to test the effectiveness
and tolerability of albiglutide alone. Second, the conclusions
from this study are limited to the population studied and might
not be applicable to the general population of patients with
type 2 diabetes.
Our findings demonstrated that albiglutide as monotherapy
for 52 weeks had a favourable benefit–risk profile in patients
with type 2 diabetes, provided durable glycaemic control, did
not promote weight gain and was generally well tolerated. The
complete 3 year results for this study will further clarify the
results reported here.
Acknowledgements The authors thank D. L. Wicks (GlaxoSmithKline)
for providing editorial assistance and for manuscript development. The
authors acknowledge the editorial support provided byM.McGee (produc-
tion of draft outline, production and incorporation of author comments and
edits within manuscript, assembly of tables and figures) and C. Barnes
(copyediting manuscript) of PPD, Inc. and editorial project management
provided by MediTech Media, Hamilton, NJ, USA. All editorial support
was funded by GlaxoSmithKline.
Portions of data from this study pertaining to the primary endpoint
were presented at the American Diabetes Association 73rd Scientific
Sessions, June 21–25, 2013, Chicago, IL, USA and at the European
Association for the Study of Diabetes 49th Annual Meeting, September
23–27, 2013, Barcelona, Spain.
Funding This study was sponsored by GlaxoSmithKline;
ClinicalTrials.gov NCT00849017 (https://clinicaltrials.gov/ct2/show/
NCT00849017). The study sponsor participated in study design, data
collection, review, analysis and report writing. All authors had full
access to study data. MAN reviewed the trial report (signatory
investigator), had full access to study data and had final responsibility
for publication submission.
Duality of interest MAN has participated in advisory boards or was
invited as speaker by Amylin Pharmaceuticals, AstraZeneca, Berlin
Chemie, Boehringer Ingelheim, Bristol-Myers Squibb, Diartis Pharma-
ceuticals, Eli Lilly, GlaxoSmithKline, Hoffmann-La Roche, Intarcia
Therapeutics, Janssen Global Services, MannKind Corp., Merck Sharp
and Dohme GmbH, Novo Nordisk, Novartis, Sanofi, Takeda, Versartis
andWyeth Research. He has received research support from AstraZeneca,
Berlin Chemie, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Merck
Sharp and Dohme GmbH, MetaCure, Novartis, Roche Pharma, Novo
Nordisk and Tolerx. MWS, AJ-L, FY, CP and RRR are employed by,
and are shareholders in, GlaxoSmithKline. FYandMWS have been issued
a patent for GLP-1s in renal disease. MR has received research funding
from GlaxoSmithKline. CP is employed by PPD.
Contribution statement All authors hereby approve the document and
attest to fulfilling all three ICMJE criteria for authorship: substantial con-
tribution to conception and design, acquisition of data, or analysis and
interpretation of data; drafting the article or revising it critically for im-
portant intellectual content and final approval of the version to be pub-
lished. MAN is the guarantor of this work and, as such, takes full respon-
sibility for the integrity of the data and the accuracy of the data analysis.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Garber AJ, Abrahamson MJ, Barzilay JI et al (2013) AACE com-
prehensive diabetes management algorithm 2013. Endocr Pract
19:327–336
2. Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of
hyperglycemia in type 2 diabetes, 2015: a patient-centered ap-
proach: update to a position statement of the American Diabetes
Association and the European Association for the Study of
Diabetes. Diabetes Care 38:140–149
3. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G,
Gregg EW (2013) Achievement of goals in U.S. diabetes care,
1999-2010. N Engl J Med 368:1613–1624
4. Esposito K, Chiodini P, Bellastella G, Maiorino MI, Giugliano D
(2012) Proportion of patients at HbA1c target <7% with eight clas-
ses of antidiabetic drugs in type 2 diabetes: systematic review of
218 randomized controlled trials with 78 945 patients. Diabetes
Obes Metab 14:228–233
5. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like
peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in
type 2 diabetes. Lancet 368:1696–1705
6. Matthews JE, Stewart MW, De Boever EH et al (2008)
Pharmacodynamics, pharmacokinetics, safety, and tolerability of
albiglutide, a long-acting glucagon-like peptide-1 mimetic, in pa-
tients with type 2 diabetes. J Clin Endocrinol Metab 93:4810–4817
7. Bush MA, Matthews JE, De Boever EH et al (2009) Safety, toler-
ability, pharmacodynamics and pharmacokinetics of albiglutide, a
long-acting glucagon-like peptide-1 mimetic, in healthy subjects.
Diabetes Obes Metab 11:498–505
8. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M, Albiglutide
Study Group (2009) Potential of albiglutide, a long-acting GLP-1
receptor agonist, in type 2 diabetes: a randomized controlled trial
Diabetologia (2016) 59:266–274 273
exploring weekly, biweekly, and monthly dosing. Diabetes Care
32:1880–1886
9. Pratley RE, Nauck MA, Barnett AH et al (2014) Once weekly
albiglutide versus once-daily liraglutide in patients with type 2 di-
abetes inadequately controlled on oral drugs (HARMONY 7): a
randomised, open-label, multicentre, non-inferiority phase 3 study.
Lancet Diabetes Endocrinol 2:289–297
10. Rosenstock J, Fonseca VA, Gross JL et al (2014) Advancing basal
insulin replacement in type 2 diabetes inadequately controlled with
insulin glargine plus oral agents: a comparison of adding
albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily
prandial insulin lispro. Diabetes Care 37:2317–2325
11. Ahren B, Johnson SL, Stewart M et al (2014) HARMONY 3: 104-
week randomized, double-blind, placebo- and active-controlled trial
assessing the efficacy and safety of albiglutide compared with pla-
cebo, sitagliptin, and glimepiride in patients with type 2 diabetes
taking metformin. Diabetes Care 37:2141–2148
12. Home P, Shamanna P, Stewart M et al (2014) Efficacy and tolera-
bility of albiglutide versus placebo and versus pioglitazone over
1 year in people with type 2 diabetes currently taking metformin
and glimepiride: HARMONY 5. Diabetes Obes Metab 17:179–187
13. Reusch J, Stewart MW, Perkins CM et al (2014) Efficacy and safety
of once-weekly GLP-1 receptor agonist albiglutide (HARMONY
1): 52-week primary endpoint results from a randomized, double-
blind, placebo-controlled, trial in patients with type 2 diabetes
mellitus not controlled on pioglitazone, with or without metformin.
Diabetes Obes Metab 16:1257–1264
14. Weissman PN, Carr MC, Ye J et al (2014) HARMONY 4:
randomised clinical trial comparing once-weekly albiglutide and
insulin glargine in patients with type 2 diabetes inadequately con-
trolled with metformin with or without sulfonylurea. Diabetologia
57:2475–2484
15. Leiter LA, Carr MC, Stewart M et al (2014) Efficacy and safety of
the once weekly GLP-1 receptor agonist albiglutide versus
sitagliptin in patients with type 2 diabetes mellitus and renal impair-
ment: a randomized, phase 3 study. Diabetes Care 37:2723–2730
16. Workgroup on Hypoglycemia, American Diabetes Association
(2005) Defining and reporting hypoglycemia in diabetes: a report
from the American Diabetes Association Workgroup on
Hypoglycemia. Diabetes Care 28:1245–1249
17. White IR, Bamias C, Hardy P, Pocock S, Warner J (2001)
Randomized clinical trials with added rescue medication: some
approaches to their analysis and interpretation. Stat Med
20:2995–3008
18. Grunberger G, Chang A, Garcia Soria G, Botros FT, Bsharat R,
Milicevic Z (2012) Monotherapy with the once-weekly GLP-1 an-
alogue dulaglutide for 12 weeks in patients with type 2 diabetes:
dose-dependent effects on glycaemic control in a randomized, dou-
ble-blind, placebo-controlled study. Diabet Med 29:1260–1267
19. Moretto TJ, Milton DR, Ridge TD et al (2008) Efficacy and toler-
ability of exenatide monotherapy over 24 weeks in antidiabetic
drug-naive patients with type 2 diabetes: a randomized, double-
blind, placebo-controlled, parallel-group study. Clin Ther
30:1448–1460
20. Fonseca VA, Alvarado-Ruiz R, Raccah D et al (2012) Efficacy and
safety of the once-daily GLP-1 receptor agonist lixisenatide in
monotherapy: a randomized, double-blind, placebo-controlled trial
in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care
35:1225–1231
21. Garber A, Henry R, Ratner R et al (2009) Liraglutide versus
glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a
randomised, 52-week, phase III, double-blind, parallel-treatment
trial. Lancet 373:473–481
22. Meier JJ (2012) GLP-1 receptor agonists for individualized treat-
ment of type 2 diabetes mellitus. Nat Rev Endocrinol 8:728–742
23. Aroda VR, Ratner R (2011) The safety and tolerability of GLP-1
receptor agonists in the treatment of type 2 diabetes: a review.
Diabetes Metab Res Rev 27:528–542
24. Victoza [package insert] (2015) Novo Nordisk Inc., Plainsboro, NJ.
Available from www.novo-pi.com/victoza.pdf, accessed
6 Oct 2015
25. Byetta [package insert] (2015) AstraZeneca Pharmaceuticals LP,
Wilmington, DE. Available from www.azpicentral.com/byetta/pi_
byetta.pdf#page=1, accessed 6 Oct 2015
26. Hayes MR (2012) Neuronal and intracellular signaling pathways
mediating GLP-1 energy balance and glycemic effects. Physiol
Behav 106:413–416
27. Cabou C, Campistron G, Marsollier N et al (2008) Brain glucagon-
like peptide-1 regulates arterial blood flow, heart rate, and insulin
sensitivity. Diabetes 57:2577–2587
274 Diabetologia (2016) 59:266–274
